GM20378
LCL from B-Lymphocyte
Description:
CEROID LIPOFUSCINOSIS, NEURONAL 2, LATE INFANTILE TYPE; CLN2
CLN2 GENE; CLN2
Repository
|
NIGMS Human Genetic Cell Repository
|
Subcollection |
Heritable Diseases Lysosomal Storage Diseases |
Class |
Disorders of the Nervous System |
Biopsy Source
|
Peripheral vein
|
Cell Type
|
B-Lymphocyte
|
Tissue Type
|
Blood
|
Transformant
|
Epstein-Barr Virus
|
Sample Source
|
LCL from B-Lymphocyte
|
Relation to Proband
|
proband
|
Confirmation
|
Molecular characterization before cell line submission to CCR
|
Species
|
Homo sapiens
|
Common Name
|
Human
|
Remarks
|
|
IDENTIFICATION OF SPECIES OF ORIGIN |
Species of Origin confirmed by LINE assay |
|
tripeptidyl-peptidase I |
According to the submitter biochemical test results for this subject showed decreased enzyme activity. EC Number: 3.4.14.9 |
|
Gene |
CLN2 |
Chromosomal Location |
11p15.5 |
Allelic Variant 1 |
; CEROID LIPOFUSCINOSIS, NEURONAL 2 |
Identified Mutation |
IVS5-1G>A |
|
Gene |
CLN2 |
Chromosomal Location |
11p15.5 |
Allelic Variant 2 |
G296-R297ins6[IVS7-18]; CEROID LIPOFUSCINOSIS, NEURONAL 2 |
Identified Mutation |
4188A>G |
Remarks |
Clinically affected; slow speech at age 2 years; intelligence regressed at age 3 years; seizures at age 3 years; movement dysfunction at age 3.5 years; EM showed curvilinear profile; deficient lysosomal tripeptidyl peptidase 1 activity; donor subject is a compound heterozygote: one allele has a G>A transition of the consensus AG 3-prime splice acceptor site immediately preceding 523T of the cDNA sequence in the CLN2 (TPP1) gene [IVS5-1G>A] and a second allele has an A>G transition at nucleotide 4188 in intron 7 of the CLN2 (TPP1) gene [4188A>G] resulting in an inframe insertion of 6 amino acids between G296 and R297 [IVS7-18].
|
Split Ratio |
1:2 |
Temperature |
37 C |
Percent CO2 |
5% |
Medium |
Roswell Park Memorial Institute Medium 1640 with 2mM L-glutamine or equivalent |
Serum |
15% fetal bovine serum Not Inactivated |
Substrate |
None specified |
Subcultivation Method |
dilution - add fresh medium |
Supplement |
- |
|
|